Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)
This clinical trial is testing a combination of two drugs, ZEN-3694 and talazoparib, to see if they can shrink advanced solid tumors. Researchers want to find out how well this drug combination works and how patients' specific genes affect their response to the treatment.
You may be able to join if you have an advanced solid tumor that has spread or cannot be removed by surgery, and standard treatments are no longer working. Participants also need to have specific genetic changes, such as a BRCA1 or BRCA2 gene mutation, and meet other health requirements.
Participants will take the study medications and undergo regular check-ups, which include imaging scans like CT or MRI, blood tests, and small tissue samples called biopsies. Doctors will closely monitor your health and how your tumor responds to the treatment.
This study has multiple locations in California, including Duarte, Irvine, and La Jolla. The study is currently active but is not looking for new participants right now.
- 1Tests a combination of two targeted cancer medications: ZEN-3694 and talazoparib.
- 2Focuses on patients with advanced solid tumors and specific genetic mutations.
- 3Involves regular health monitoring, imaging scans, and tissue samples.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.